Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual ...(Loyola University Chicago William J. ...),Health

Date:6/4/2009

Loyola University Chicago William J. Ward, Jr., MBA Associate Professor Director, MHS Degree in Health Finance and Management Sommer Scholars Program Faculty Director Johns Hopkins Bloomberg School of Public Health Fred C. Tenover, Ph.D., D (ABMM) Senior Director, Scientific Affairs, Cepheid Adjunct Professor of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

Healthcare-associated infections exact a significant toll on human life, and are among the top ten leading causes of death in the United States. Recent reports estimate hospital stays for Methicillin-resistant Staphylococcus aureus (MRSA) infection have more than tripled since 2000 and represent $20 billion in excess healthcare costs each year. Similarly, Clostridium difficile infections have been increasing in incidence and severity, and have become a substantive and growing burden in hospitalized patients, prompting the need for earlier and accurate detection.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly impor
'/>"/>

SOURCE Cepheid Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results